News & Analysis as of

Bristol-Myers Squibb Enforcement Actions Pharmaceutical Industry

Barnea Jaffa Lande & Co.

Increased Enforcement in Pharmaceutical Sector: BMS and Neopharm to Pay ILS Tens of Millions for Delaying Entry of Competing Drug

The Israel Competition Authority (ICA) recently published a draft consent decree signed with the international pharmaceutical company Bristol-Myers Squibb (BMS) and the Israeli pharmaceutical distributor Neopharm. Under the...more

Goodwin

Antitrust & Competition Life Sciences Year in Review 2023

Goodwin on

Despite increasingly aggressive rhetoric from the agencies, 2022 was largely characterized as “business as usual” in the antitrust world. In contrast, 2023 featured a significant step up in enforcement activity, including...more

Dorsey & Whitney LLP

SEC, Bristol-Myers Settle FCPA Charges

Dorsey & Whitney LLP on

FCPA procedures, internal controls and travel, entertainment and gifts were at the center of the SEC’s latest FCPA action. The action names as a Respondent Bristol-Myers Squibb Company and focuses on its efforts to sell...more

Thomas Fox - Compliance Evangelist

Bristol-Myers Squibb FCPA Enforcement Action

Yesterday, the Securities and Exchange Commission (SEC) announced a Foreign Corrupt Practices Act (FCPA) enforcement action against Bristol-Myers Squibb Company (BMS) for the actions of the company’s joint venture (JV) in...more

4 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide